Increasing evidence suggests that treatment with the low molecular weight heparin
enoxaparin during percutaneous coronary intervention (PCI) is safe and effective. We …

This study assessed the pharmacokinetics, safety and efficacy of intravenous enoxaparin in
patients undergoing percutaneous coronary intervention (PCI). Sixty consecutive patients …

Objectives: To evaluate the use of citrated clotting time (CCT) during percutaneous coronary
intervention (PCI) in both emergent and elective scenarios and using intravenous (IV) or …

Objectives: This study was designed to examine a unique and low dose of intravenous
enoxaparin in elective percutaneous coronary intervention (PCI) that would be applicable to …

The objective of this study was to evaluate the pharmacokinetic response to intravenous (IV)
enoxaparin given 8–12 hr after subcutaneous (SC) dosing in patients undergoing …

We sought to determine the safety and efficacy of enoxaparin versus unfractionated heparin
during percutaneous coronary intervention (PCI). Four hundred ninety-three consecutive …

Background. The use of low-molecular weight heparin (LMWH) during percutaneous
coronary intervention (PCI) has been limited by the presumed inability to monitor its …

Background The best anticoagulation strategy for patients undergoing percutaneous
coronary intervention (PCI) remains controversial. The primary objective of this study was to …

Background: Enoxaparin has gained wide acceptance in patients with acute coronary
syndromes. However, there is uncertainty regarding management of patients who require …

Background Despite its limitations, unfractionated heparin has been the standard
anticoagulant used during percutaneous coronary intervention (PCI). Several small studies …